PDUFA Date
PDUFA Date: rp1
- Company
- Replimune Group, Inc. (REPL)
- Drug
- rp1
- Indication
- advanced melanoma
Other upcoming events for REPL
Phase 2 StartPhase 2 Start: A Phase 2 Study of RP2 With Tivozanib in Patients With Metastatic Renal Carcinoma After Progression
Phase 3 ReadoutPhase 3 Topline: Phase 3 Study to Evaluate the Safety and Efficacy of AAV5-hRKp.RPGR for the Treatment of Japanese X-
Phase 3 ReadoutPhase 3 Topline: A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combinati
Phase 3 ReadoutPhase 3 Topline: Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.